We propose that all considered effects of GPX4 on the risk of CS can be mediated by three following mechanisms
References Novo Nordisk
In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide lost an average of 22.5 percent of their body weight at 72 weeks (Jastreboff et al., NEJM , 2022), compared to roughly 15 percent with semaglutide 2.4 mg in the STEP 1 trial (Wilding et al., NEJM , 2021)
J Biol Chem 285:93469356 Dursun N, Taskin E, Ozturk F (2011) Protection against adriamycin-induced cardiomyopathy by carnosine in rats: role of endogenous antioxidants
Documentation of medical necessity and physician oversight significantly improves reimbursement prospects
Insulin and glucagon dynamics GLP-1 receptor agonists enhance insulin secretion in a glucose-dependent manner, meaning they boost insulin only when blood sugar is elevated